<DOC>
	<DOCNO>NCT02618824</DOCNO>
	<brief_summary>Terminal warm blood cardioplegia ( TWBC ) show enhance myocardial protection adult patient . Even pediatric patient , use cold blood cardioplegia follow administration TWBC provide cardioprotective effect similar adult patient . Histidine-tryptophan-ketoglutarate ( HTK ) , attractive cardiac surgeon administer single dose claim offer myocardial protection period 180 minute allow performance complex procedure without interruption . Merging use TWBC use HTK cardioplegia , especially pediatric cardiac case , investigate . This technique expect provide long ischemic time protective effect reperfusion injury .</brief_summary>
	<brief_title>Role Terminal Warm Blood Cardioplegia Myocardial Protection Use Histidine-Tryptophan-Ketoglutarate Cardioplegia Complex Congenital Heart Surgery</brief_title>
	<detailed_description>The design study randomize control trial child young 5 year old undergoing heart surgery cardiopulmonary bypass . The objective study assess role TWBC use HTK cardioplegia compare use HTK cardioplegia alone open heart surgery complex congenital heart disease . This study conduct National Cardiac Centre Harapan Kita Hospital Indonesia . Surgery perform operating room Pediatric Congenital Cardiac Surgery Unit . This study use non-probability consecutive sampling . The sample pediatric patient complex congenital heart disease meet inclusion criterion exclude exclusion criterion . Patients divide two group , treatment group receive HTK cardioplegia TWBC , control group receive HTK cardioplegia alone . Hearts arrest HTK solution cardiac operation . HTK cardioplegia give aortic root dose 50-60 ml/kg aortic cross-clamped . For treatment group , TWBC give shortly aortic cross clamp remove dose 10 15 ml/kg temperature 34 36 oCelcius . TWBC mixture blood HTK kardioplegia composition four one . The outcome study malondialdehyde marker reperfusion injury due oxidative stress , caspase-3 marker apoptosis , cTn-I marker myocardial cell damage incidence low cardiac output syndrome .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Procaine</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>Patient diagnose complex cyanotic congenital heart disease schedule pediatric cardiac surgery Aristotle score 8 Parents patient write informed consent agree follow research procedure Patient diagnose congenital defect Patient diagnose rare congenital heart defect high mortality rate ( hypoplastic leave heart syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>